Your browser doesn't support javascript.
loading
Clear Cell Renal Cell Carcinoma: Characterizing the Phenotype of Von Hippel-Lindau Mutation Using MRI.
Bai, Xu; Peng, Cheng; Liu, Baichuan; Zhou, Shaopeng; Guo, Huiping; Hao, Yuwei; Liu, Haili; Chen, Yijian; Liu, Xin; Ning, Xueyi; Ma, Yuanhao; Zhao, Jian; Li, Lin; Ye, Huiyi; Ma, Xin; Wang, Haiyi.
Afiliación
  • Bai X; Medical School of Chinese PLA, Beijing, China.
  • Peng C; Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Liu B; Department of Radiology, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Zhou S; Department of Urology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Guo H; Medical School of Chinese PLA, Beijing, China.
  • Hao Y; Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Liu H; Medical School of Chinese PLA, Beijing, China.
  • Chen Y; Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Liu X; Medical School of Chinese PLA, Beijing, China.
  • Ning X; Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Ma Y; Medical School of Chinese PLA, Beijing, China.
  • Zhao J; Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Li L; Department of Radiology, Fourth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Ye H; Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Ma X; Department of Radiology, Chinese PLA 920 Hospital, Kunming, China.
  • Wang H; Medical School of Chinese PLA, Beijing, China.
J Magn Reson Imaging ; 2024 Aug 28.
Article en En | MEDLINE | ID: mdl-39193825
ABSTRACT

BACKGROUND:

The von Hippel-Lindau (VHL) mutation is an important alteration in clear cell renal cell carcinoma (ccRCC); however, its imaging phenotype remains unclear.

PURPOSE:

To investigate whether MRI features can reflect the VHL mutation status. STUDY TYPE Retrospective. FIELD STRENGTH/SEQUENCE 3 T/fast spin echo T2-weighted, spin-echo echo planar diffusion-weighted, gradient recalled echo T1-weighted, gradient recalled echo chemical-shift T1-weighted, and contrast-enhanced gradient recalled echo T1-weighted sequences. POPULATION One hundred five patients with ccRCC who underwent preoperative contrast-enhanced MRI and subsequent genomic sequencing 59 consecutive patients from our institution (38 [64.41%] with VHL mutations) formed a training cohort, and 46 from The Cancer Genome Atlas (TCGA) database (24 [52.17%] with VHL mutations) formed an independent test cohort. ASSESSMENT Two radiologists, with 23 and 33 years of experience respectively, jointly evaluated the semantic MRI features of the primary lesion in ccRCCs to propose potential features related to VHL mutations in both cohorts. Three additional readers, with 5, 7, and 10 years of experience respectively, independently reviewed all lesions to assess the interobserver agreement of MRI features. A VHL mutational likelihood score (VHL-MULIS) system was constructed using the training cohort and validated using the independent test cohort. STATISTICAL TESTS Fisher's test or chi-square test, t-test or Mann-Whitney U test, logistic regression, Cohen's kappa (κ), area under the receiver operating characteristic curve (AUC). A two-sided P value <0.05 was considered statistically significant.

RESULTS:

In both the local and public cohorts, T2-weighted signal intensity and presence of microscopic fat from primary lesions were significantly associated with VHL mutation status. The VHL-MULIS incorporated maximum diameter, T2-weighted signal intensity, and presence of microscopic fat in the training cohort and demonstrated promising diagnostic ability (AUC, 0.82; sensitivity, 0.79; specificity, 0.82) and substantial interobserver agreement (κ, 0.787) in the test cohort. DATA

CONCLUSION:

The VHL mutation exhibited a distinct MRI phenotype. Integrating multiple semantic MRI features has potential to reflect the mutation status in patients with ccRCC. EVIDENCE LEVEL 3 TECHNICAL EFFICACY Stage 2.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Magn Reson Imaging Asunto de la revista: DIAGNOSTICO POR IMAGEM Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Magn Reson Imaging Asunto de la revista: DIAGNOSTICO POR IMAGEM Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos